Nexalin Technology (NASDAQ:NXL – Get Free Report) is one of 76 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its peers? We will compare Nexalin Technology to similar businesses based on the strength of its profitability, valuation, risk, earnings, institutional ownership, analyst recommendations and dividends.
Volatility & Risk
Nexalin Technology has a beta of 5.53, indicating that its share price is 453% more volatile than the S&P 500. Comparatively, Nexalin Technology’s peers have a beta of 12.64, indicating that their average share price is 1,164% more volatile than the S&P 500.
Valuation & Earnings
This table compares Nexalin Technology and its peers top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Nexalin Technology | $110,000.00 | -$4.65 million | -2.64 |
Nexalin Technology Competitors | $986.78 million | $82.19 million | -9.17 |
Analyst Recommendations
This is a breakdown of current ratings for Nexalin Technology and its peers, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Nexalin Technology | 0 | 0 | 0 | 0 | N/A |
Nexalin Technology Competitors | 252 | 769 | 2038 | 101 | 2.63 |
As a group, “Electromedical equipment” companies have a potential upside of 25.91%. Given Nexalin Technology’s peers higher probable upside, analysts plainly believe Nexalin Technology has less favorable growth aspects than its peers.
Insider & Institutional Ownership
0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 45.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 27.7% of Nexalin Technology shares are owned by company insiders. Comparatively, 15.2% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Nexalin Technology and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Nexalin Technology | -3,088.12% | -154.84% | -122.94% |
Nexalin Technology Competitors | -152.14% | -47.46% | -5.34% |
Summary
Nexalin Technology peers beat Nexalin Technology on 8 of the 10 factors compared.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.